Clinical trials have demonstrated significant interest in its application for obesity and type 2 diabetes research
Products like detox teas and fat-burning supplements are becoming popular as they promise the results without any strict diet or exercise
That said, fiber-rich foods (legumes, oats, onions, Jerusalem artichoke), higher-protein meals, and fermented foods can each modestly support your body's own GLP-1 and satiety signaling through the microbiome and L-cell pathways described above
Researchers should use one compound at a time
Benefits of the Carnivore Diet The carnivore diet remains highly controversial, though some individuals report perceived benefits
Current Research Status and Future Directions Where We Are Now (2026) Retatrutide is currently in Phase 3 clinical development under Eli Lilly's TRIUMPH program, which includes multiple trials: TRIUMPH-3 Obesity without type 2 diabetes Evaluating 12mg vs 9mg vs placebo in adults with BMI 30 or 27 with comorbidities TRIUMPH-4 Obesity with type 2 diabetes Testing efficacy and safety in patients with both conditions (preliminary: 28.7% weight loss) MASLD/NASH Trials Metabolic dysfunction-associated steatotic liver disease Leveraging glucagon's liver fat reduction effects Cardiovascular Outcomes Long-term CV safety and benefits Following precedent of STEP and SURMOUNT trials for GLP-1 drugs Timeline to FDA Approval 2023: Phase 2 results published (NEJM) 2024-2026: Phase 3 trials ongoing (TRIUMPH program) 2026-2027: Anticipated FDA submission (if trials successful) 2027-2028: Potential FDA approval and commercial launch What Researchers Are Watching The main questions Phase 3 needs to answer: Long-term efficacy: Does weight loss plateau or continue beyond 48 weeks
&srotate=0)
